Anti-SARS-CoV-1, Spike RBD (Clone COV1-58) -Purified No Carrier Protein

Specificity: COV1-58 targets the receptor-binding domain (RBD) of the SARS-CoV-1 prefusion spike protein (S2), located on the viral surface. Antigen Distribution: Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background: SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. COV1-58 is a monoclonal antibody that specifically targets the receptor-binding domain (RBD) of the SARS-CoV-1 spike protein. This antibody does not block the ACE2 receptor directly but serves as a neutralizer by preventing the virus from entering host cells. By binding to the RBD, COV1-58 likely interferes with the spike protein's ability to engage with the ACE2 receptor, thus neutralizing the virus. Its specificity for the RBD makes COV1-58 a crucial tool in neutralizing SARS-CoV-1 and offers potential in therapeutic applications, including the design of antibody cocktails to improve treatment efficacy.